Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
International Journal of Radiation Oncology*Biology*Physics · 2023
DOI: 10.1016/j.ijrobp.2023.01.006 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023. Verfasst von Casey L Liveringhouse und 24 weiteren Autor:innen. Beteiligte Einrichtung: H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, Florida. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Melanoma, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bristol-Myers Squibb, NCI.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: We hypothesized that concurrent ipilimumab with chemoradiationtherapy (chemoRT) followed by maintenance nivolumab would be safe for patients with unresectable stage III non-small cell lung cancer (NSCLC). We aimed to assess the safety (phase 1) and the 12-month progression-free survival (PFS) (phase 2) in a multi-institution prospective trial. METHODS AND MATERIALS: Eligible patients had unresectable stage III NSCLC. The treatment included platinum doublet chemotherapy with concurrent thoracic radiation therapy to 60 Gy in 30 fractions and ipilimumab (1 mg/kg) delivered during weeks 1 and 4. After chemoRT, maintenance nivolumab (480 mg) was given every 4 weeks for up to 12 cycles. Adverse events (AEs) were assessed according to the Common Terminology Criteria for Adverse Events, version 5.0. Survival analyses were performed with Kaplan Meier (KM) methods and log-rank tests. RESULTS: The trial was discontinued early after enrolling 19 patients without proceeding to the phase 2 component because of unacceptable toxicity. Sixteen patients (84%) had grade ≥3 (G3+) possible treatment-related toxicity, most commonly pulmonary AEs (n = 8, 42%). Fourteen patients (74%) discontinued study therapy early because of AEs (n = 12, 63%) or patient choice (n = 2, 11%). Eleven patients (58%) experienced G2+ pulmonary toxicity with median time to onset 4.1 months (95% CI 2.6-not reached [NR]), and 12-month freedom from G2+ pulmonary toxicity 37% (95% CI, 16-59). Five patients had G5 AEs, including 3 with G5 pulmonary AEs (1 respiratory failure with pneumonitis and pulmonary embolism, 1 pneumonia/chronic obstructive pulmonary disease exacerbation, 1 pulmonary fibrosis). Despite toxicities, the median PFS was 19.2 months (95% CI 6.1-NR) and the median overall survival was NR (95% CI 6.1-NR) with median follow-up of 30.1 months by the reverse KM method. CONCLUSIONS: Concurrent ipilimumab with chemoRT for unresectable stage III NSCLC is associated with pulmonary toxicity that may limit opportunities for improved outcomes. Future studies aiming to incorporate ipilimumab or other anti-CTLA4 therapies into management of unresectable stage III NSCLC should consider careful measures to minimize toxicity risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, Florida.
- H. Lee Moffitt Cancer Center and Research Institute, Department of Thoracic Oncology, Tampa, Florida.
- University of North Carolina Hospitals, Department of Radiation Oncology, Chapel Hill, North Carolina.
- Duke University Medical Center, Department of Medicine, Division of Medical Oncology, Durham, North Carolina.
- Duke University Medical Center, Department of Radiation Oncology, Durham, North Carolina.
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiology, Tampa, Florida.
Förderung
- NCI NIH HHS
- Bristol-Myers Squibb
- NCI
Zitieren
APA
Liveringhouse, C. L., Latifi, K., Asous, A. G., Lam, N. B., Rosenberg, S. A., Dilling, T. J., MacMillan, G. V., Chiappori, A. A., Haura, E. B., Creelan, B., Gray, J. E., Tanvetyanon, T., Shafique, M. R., Saltos, A. N., Weiner, A. A., Clarke, J., Kelsey, C. R., Kim, S., Caudell, J. J., …, & Perez, B. A. (2023). Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2023.01.006
Vancouver
Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, et al. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 2023. doi:10.1016/j.ijrobp.2023.01.006
BibTeX
@article{Liveringhouse2023,
author = {Liveringhouse, Casey L and Latifi, Kujtim and Asous, Amalin G and Lam, Nghi B and Rosenberg, Stephen A and Dilling, Thomas J and MacMillan, Gretchen V and Chiappori, Alberto A and Haura, Eric B and Creelan, Ben and Gray, Jhanelle E and Tanvetyanon, Tawee and Shafique, Michael R and Saltos, Andreas N and Weiner, Ashley A and Clarke, Jeffrey and Kelsey, Christopher R and Kim, Sungjune and Caudell, James J and Rose, Trevor A and Conejo-Garcia, Jose R and Li, Jiannong and Schell, Michael J and Antonia, Scott J and Perez, Bradford A},
title = {Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2023},
doi = {10.1016/j.ijrobp.2023.01.006}
}
EUVIMED